Introduction
Apoptosis is known to play a signi®cant role in the etiology of cancer (Wyllie, 1997) , particularly apoptosis mediated by the cell surface receptor CD95 (Fas/APO-1) (Itoh et al., 1991) . In the CD95-mediated apoptotic pathway, engagement of the receptor with its natural ligand results in the formation of a receptor-associating DISC complex that includes FADD and caspase-8 (Peter and Krammer, 1998) . Followed by a series of caspase activation steps that may involve the mitochondria (Scadi et al., 1998) , this signaling cascade leads to apoptosis. However, CD95 expression does not always correlate with susceptibility to CD95-mediated apoptosis, and a number of inhibitors which operate downstream of receptor crosslinking have been identi®ed. These include the CD95-speci®c inhibitors sentrin (Okura et al., 1996) and FAP-1 (Sato et al., 1995) , which interact directly with the receptor; FLIP (Irmler et al., 1997) , which associates with FADD; ARC (Koseki et al., 1998) , a caspase-8 inhibitor; IEX-1L (Wu et al., 1998) , which inhibits both CD95-and TNF-mediated apoptosis; and FAIM (Schneider et al., 1999) , whose mechanism of action remains to be elucidated. There are, therefore, inhibitors of dierent steps of the signal transduction pathway.
It is becoming increasingly apparent that some cancer cells are able to escape cell death by interfering with the CD95 signaling cascade. For instance, the expression of CD95 ligand on the surface of some cancer cells may enable them to trigger apoptosis in invading cytotoxic T cells that express CD95 (Nagata, 1996) . Other cancer cells may evade cell death through reduced expression of CD95 (Tsuruda et al., 1999) . Up-regulation of the apoptosis inhibitor cFLIP has been found in melanoma cells, suggesting another mechanism by which cancer cells are able to circumvent destruction by the immune system (French and Tschopp, 1999) . Two recent reports have established that cFLIP, in particular, and perhaps other apoptosis suppressors, can in fact be classi®ed as tumor progression factors (Djerbi et al., 1999; Medema et al., 1999) . It has also been established that some chemotherapeutic drugs, such as doxorubicin, methotrexate and etoposide, interfere with the CD95 signaling pathway. Both doxorubicin and methotrexate have been shown to induce CD95 ligand synthesis in some cancer cells (Friesen et al., 1996) , and etoposide has been shown to induce one of the proteases in the CD95 apoptotic signaling cascade (Boesen-de Cock et al., 1998) .
Using a functional screening system, we set out to ®nd novel genes involved in apoptosis initiated through CD95 ligation. Variations on this mammalian expression system (Yates et al., 1985) have been successfully used to identify both known and novel genes involved in apoptosis control, such as Drosophila requiem (Gabig et al., 1994) , human Bcl-2 and Bcl-x (Jaattela et al., 1995) , human ALG-2 and ALG-3 (Vito et al., 1996) and human DAP-1, DAP-2 and DAP-Kinase Kissil et al., 1995) . Our system incorporated a human bone marrow cDNA library as the source of apoptosis regulators, human Jurkat T cells as the screening host, and CD95 antibody as the apoptotic stimulus. Here we report on two novel regulators of CD95-mediated apoptosis in Jurkat cells.
Results

Je2 suppresses CD95-mediated apoptosis
To ®nd novel genes with the ability to control apoptosis in lymphocytes, a human bone marrow cDNA library was screened for genes able to suppress Oncogene (2000) 19, 3774 ± 3781 ã 2000 Macmillan Publishers Ltd All rights reserved 0950 ± 9232/00 $15.00 www.nature.com/onc cell death produced by CD95 engagement in Jurkat human T cells. Using an episomal retrieval functional expression cloning system (Yates et al., 1985) , a cDNA was identi®ed (Je2), which inhibited apoptosis in the Jurkat/Epstein Barr nuclear antigen-1 containing clone JEB2, and which again suppressed CD95-mediated apoptosis after extraction of the episome from the CD95-resistant cells and re-introduction into JEB2 cells. Cells containing the re-introduced cDNA were subjected to another round of CD95 screening, the episomes extracted and the cDNA sequenced. Four separate re-transfections of the episome, into four dierent Jurkat clones (JEB1, JEB3, JEB4, JEB5) similarly resulted in suppression of CD95-mediated apoptosis, whereas transfection of control DNA did not (Figure 1 ). These re-transfection studies indicated that suppression of apoptosis was directly attributable to the presence of Je2.
Je2 is part of the LUCA-15 gene locus
Similarity sequence analysis of nucleotide databases revealed that Je2 maps to the LUCA22 human chromosomal locus (Accession #U73168) at 3p21.3, and has no signi®cant homology to any other sequence in the databanks. Je2 lies within an intron of the 2.6 kb LUCA-15 gene (Accession #U23946) , in the opposite orientation to the direction of LUCA-15 transcription. The fact that Je2 was found in an intronic region raised the possibility that Je2 represented either a heteronuclear RNA or genomic contaminant, rather than cDNA from a mature messenger RNA sequence. Expression of transcripts containing Je2 sequence was therefore examined.
By RT ± PCR it was shown that Je2 is part of an RNA that incorporates LUCA-15 sequence (Figure 2 ). Experiments using primers recognizing both LUCA-15 and the intronic region containing Je2 sequence, resulted in the identi®cation of two RNA splice variants (Figure 2ciii , iv). These primers, LU15(2) and LS5 (Figure 2a ), revealed two transcripts in both Jurkat and spleen cells, which when sequenced were found to dier from each other by one 481 bp intron (intron 5), relative to the LUCA-15 databank sequence. Primers LU15(G) and LU15(3), which recognize both the intronic region containing Je2 and 3'-LUCA-15 sequence, respectively, were then used to determine by PCR whether the Je2 containing intron is linked to downstream LUCA-15 sequence. In an RT ± PCR reaction these primers produced a fragment of 194 bp, thereby con®rming linkage: a longer 1274 bp fragment resulted from unspliced DNA present in a genomic control (data not shown). It was also noted that no further splice variations were detected using LU15(G) and LU15(3). Interestingly, using primers LU15(2) and LU15(3), two RNA splice variants were identi®ed, neither of which contained intron 5 or 6 sequences ( Figure 2b ). The 379 bp PCR product observed in both Jurkat and spleen cells was found by sequence analysis to be homologous to LUCA-15 sequence (Figure 2ci ), whereas a 309 bp PCR product observed only in spleen cells was homologous to LUCA-15 sequence lacking exon 6 (Figure 2cii ). No larger products, representing the two intron-containing variants (expected sizes approximately 3.3 and 2.8 kb), were observed. Failure to detect the two larger transcripts in the same PCR reaction as the smaller transcripts could be a result of their relatively low abundance, in addition to their larger size compared to the intron-less transcripts, leading to preferential ampli®cation of the smaller, more abundant transcripts.
Northern blot analyses were then carried out in order to further examine transcript abundance and to observe transcript sizes. Blots were probed using Je2-speci®c and LUCA-15-speci®c double-stranded DNA probes, against mRNA from a range of human tissues of lymphoid, non-lymphoid and cancer origin (Figure 3 ). Based on the RT ± PCR results, the predicted sizes of full-length transcripts were as follows. If the remainder of the LUCA-15 sequence not de®ned by the primers used in the RT ± PCR experiments contained no further sequence dierences relative to the published LUCA-15 gene, then the predicted sizes of the two Je2 (intron) containing transcripts would be approximately 5.6 and 5.1 kb, and the variant missing exon 6 would be 70 bp short of 2.6 kb. In the Northern blot analyses, using the Je2-speci®c probe, a ubiquitously expressed transcript of approximately 7 kb predominated (Figure 3ai , ii, iii), although transcripts of less than 1 kb were present, and more dierentially expressed. Membranes probed with either an extreme 5'-LUCA-15 probe ( Figure 3bi ) or an extreme 3'-LUCA-15 probe ( Figure 3bii ) detected both a 7 kb transcript and a 3.5 kb transcript, con®rming the RT ± PCR results which demonstrated linkage between Je2 and LUCA-15 sequences, and further suggesting that the 7 kb transcript is an alternatively spliced mRNA molecule of the LUCA-15 gene. Band intensities also supported the previous observation, based on the RT ± PCR results, that the Je2-containing transcripts are somewhat less abundant than the non-intron-containing transcripts. In conclusion, therefore, these expression studies suggest that Je2 is not a genomic contaminant, but part of expressed LUCA-15 sequence, and ± as evidenced by its abundance on To examine the expression of LUCA-15 variants at the protein level, Western blot analysis was carried out using an antibody raised to the amino-terminus of LUCA-15 ( Figure 4 ). In all cells tested (Jurkat, TF-1 and K-562), the antibody detected one polypeptide of approximately 100 kD, which represents LUCA-15 (predicted size of 92 kD, based on the cDNA sequence of Accession #U23946). In addition, in Jurkat cells, the antibody detected a 42 kD polypeptide that has no directly corresponding mRNA, but may represent a product of proteolytic cleavage of the full-length LUCA-15. In all cells examined, a third polypeptide was recognized at 17 kD, which is predicted to arise from the 5.6 kb transcript de®ned above (including introns 5 and 6, and containing a stop codon in intron 5, Figure 2ciii ). Expression of the 17 kD product was generally weak, and detection was not consistently possible: further studies await production of new antibodies. Pre-incubation of the anti-LUCA-15 antibody with the immunizing peptide abolished recognition of all three bands (data not shown).
Je2 modulates LUCA-15 expression
It might be expected that Je2 in¯uences apoptosis by altering the expression of an antisense Je2-containing LUCA-15 variant. To test this, the expression of LUCA-15-related proteins during CD95-mediated apoptosis was examined, using the same amino terminal LUCA-15 antibody used in Figure 4 .
Je2 had a marked eect on the expression of the 100 kD LUCA-15 polypeptide ( Figure 5 ). In Jurkat cells transfected with vector only, and exposed to anti-CD95 antibody, the expression of the 100 kD and 42 kD polypeptides gradually declined: following 24 h in antibody, little of either polypeptide was detectable. This down-regulation correlated with the onset of apoptosis, as shown by caspase-3 cleavage: the 32 kD precursor caspase-3 polypeptide was cleaved to produce polypeptides of roughly 20 and 17 kD. In contrast, in Jurkat cells stably transfected with Je2, and exposed to anti-CD95 antibody, expression of the 100 and 42 kD polypeptides did not decline. Furthermore, these cells did not become apoptotic, as shown by the absence of caspase-3 cleavage products. Cell extracts were taken after 5 days growth in antibody to reinforce the observation that, whereas control cells containing vector alone were dead following 3 days in antibody, the Je2-containing cells were able to survive and proliferate. Notably, Je2 did not aect expression of the 100 kD LUCA-15 polypeptide prior to CD95 ligation, although expression of the 42 kD species was diminished. Unfortunately, since the 17 kD polypeptide, seen in Figure 4 , was not consistently observable, the eect of Je2 overexpression on protein putatively encoded by Je2-containing sequence was not able to be determined. These results do, however, con®rm that Je2 functions to suppress CD95-mediated apoptosis, and illustrate the importance of the relationship between the presence of the 100 kD LUCA-15 protein and resistance to CD95-mediated apoptosis.
A LUCA-15 splice variant that modulates apoptosis
In order to identify full-length LUCA-15 RNA splice variant cDNA's for functional analyses, a spleen library was screened. Using Je2-speci®c primers, and screening by PCR, a 2.6 kb clone was obtained, termed Clone 26. This Je2-containing clone corresponded to the alternatively spliced LUCA-15 transcript outlined in Figure 2ciii , but terminating within intron 6. Clone 26 is predicted to be a truncated variant LUCA-15 transcript, as no transcript of approximately 2.6 kb was detected by Northern blot analysis using a Je2- Figure 2ciii , its function would be preserved.
Using a zinc-inducible gene expression plasmid (Cook et al., 1996) , Clone 26 not only inhibited proliferation of Jurkat cells but also dramatically augmented CD95-mediated apoptosis (Figure 6 ). Stable Jurkat clones containing either the zinc-inducible plasmid pMTCB6 + or pMTCB6 + /Clone 26 were grown in the presence of 50 mM zinc for 50 h. To con®rm that Clone 26 was being expressed, RT ± PCR was performed on the transfected cells (Figure 6a ). Using the primers LU15(2) and LS5, bands of 1290 and 809 bp were produced in the pMTCB6 + transfected cells, representing the two Jurkat Je2 containing RNA splice variants detailed in Figure 2ciii , iv. A much stronger band of 1290 bp was produced in the pMTCB6 + /Clone 26 transfected cells, con®rming that Clone 26 was indeed being expressed. (As the zinc inducible system has high background expression levels in Jurkat cells (Sutherland et al., 2000) , Clone 26 containing cells were compared to cells transfected with vector only, also grown in zinc, and a large number of individual clones examined in order to exclude clonal variation). Following the 50 h pre-incubation in zinc, cells were cultured a further 38 h in the presence or absence of 5 ng/ml anti-CD95 antibody. In the absence of antibody, Clone 26 reduced cell proliferation compared to cells transfected with vector alone ( Figure  6b ). Furthermore, a signi®cant augmentation of CD95-mediated cell death by Clone 26 was observed in the cells exposed to antibody (Figure 6c ). Not only was cell death more rapid in the Clone 26 transfected Jurkat cells, it was initiated earlier. Therefore, apoptosis regulation in Jurkat cells can be achieved by over- 
Discussion
The human chromosomal locus 3p21.3 experiences loss of heterozygosity (LOH) in 490% of freshly microdissected primary lung cancers (Gazdar et al., 1994) , and has been shown to be involved in many other cancers, including renal, head and neck, gastrointestinal, breast and female genital tract (Kok et al., 1997) . It is assumed, as LOH is so prevalent in lung cancer, that the 3p21.3 locus harbors a tumor suppressor gene: the fact that no single locus of 3p21.3 appears to be consistently aected by LOH ± in primary tumors or tumor cell lines ± suggests that the region contains more than one tumor suppressor gene.
Here we report on the observation that two transcripts from the LUCA-15 TSG gene locus at 3p21.3 are able to modify apoptosis. Firstly, a cDNA fragment referred to as Je2 was isolated and found to suppress CD95-mediated apoptosis in Jurkat T cells. Secondly, Je2 was identi®ed to be an antisense transcript to an alternative splice variant of the putative tumor suppressor gene LUCA-15. Thirdly, overexpression of a cDNA representing this splice variant (Clone 26) in the Jurkat cells inhibited their proliferation in the absence of an extracellular apoptotic stimulus, suggesting it may independently function to induce apoptosis. In addition, the transfected cells became more sensitized to CD95-mediated apoptosis. Therefore, the alternatively spliced LUCA-15 gene variant together with its 3'-UTR antisense repressor RNA (Je2) represent a putative apoptosis regulatory system encoded in the LUCA-15 gene locus.
Regulation of gene expression by antisense RNA is common in prokaryotes (Simons and Kleckner, 1988) , and may be just as important and widespread a phenomenon in eukaryotes (Peltz and Dougherty, 1999; Vanhee-Brossollet and Vaquero, 1998) . Indeed, while once thought to exist only in the realm of viral regulation of host gene expression, it now appears that antisense regulation is a far more widespread mechanism of cellular control, involving both antisense mRNA and protein (Van Den Eynde et al., 1999) . One well characterized example is very similar to the case described here for LUCA-15, in which the 3'-UTRs of two genes from C. elegans, Lin-14 and Lin-28, contain conserved sequences that are antisense to the RNA of a third gene, Lin-4 (Moss et al., 1997; Wightman et al., 1993; Lee et al., 1993) . It is proposed that Lin-4 mRNA anneals with the mRNA 3'-UTR sequence of Lin-14 and Lin-28 in the cytoplasm, thereby forming a complex which interferes with their translation. This example provides a conceptual framework for the mechanism of action of Je2. Thus, cytoplasmic Je2-containing antisense mRNA may anneal to the 3'-UTR of the LUCA-15 intron-containing RNA splice variant, represented by Clone 26, forming a complex which prevents the translation of the variant, thereby suppressing its function as an inhibitor of cell proliferation and augmenter of CD95-mediated apoptosis. Cytoplasmic LUCA-15 message, lacking the Je2 complementary intron, would not be aected by Je2. As a consequence of the inhibition of translation of the intron-containing variant represented by Clone 26, the cells survive, and LUCA-15 remains intact, as is observed by Western blot analysis ( Figure  5) .
The existence of a number of RNA splice variants may contribute to an additional level of apoptosis regulation. Full-length LUCA-15 protein contains a number of functional motifs, including two RNA binding domain motifs, two putative zinc-®nger DNA binding motifs, and a nuclear localization sequence. Recent studies have demonstrated that recombinant proteins containing LUCA-15 RNA binding motifs speci®cally bind poly(G) RNA homopolymers in vitro (Drabkin et al., 1999) . Assuming that the splice variants delineated in Figure 2 are all part of translated sequences, and that these have the same start site as the LUCA-15 cDNA in the databanks, any protein encoded by the alternatively spliced LUCA-15 variant containing only the Je2 intron (Figure 2civ ) would retain only RNA binding domain 1 (as there is a stop codon following exon 6). The variant containing both introns (Figure 2ciii ) (the predicted 17 kD protein, equivalent to Clone 26 encoded protein), would lack all the putative identi®ed functional domains in LUCA-15 (as there is a stop codon following exon 5), and the variant only observed in spleen (Figure 2cii ) (lacking exon 6) would have RNA binding domain 1 deleted. This suggests that alternative RNA splicing may play a role in regulating apoptosis by eliminating various functional domains, and that this regulation may revolve around RNA binding.
Structural, functional and mechanistic studies required to determine the role of LUCA-15 and its splice variants as critical components of the cell death mechanism are in progress. Elucidation of this mechanism of action will help to further de®ne the CD95, and perhaps other, apoptotic pathways, and provide insights into its putative function as a tumor suppressor gene.
Materials and methods
Jurkat cell cloning and culture
To increase episomal screening eciency (Peterson and Legerski, 1991 ) the CD95-sensitive Jurkat cell clone JKM1 (Williams et al., 1998) was co-transfected (Sutherland and Williams, 1997) with pCMV.EBNA (Invitrogen), a plasmid containing the Epstein-Barr Virus Nuclear Antigen-1 gene, and pBABE.puro (kindly provided by Prof Farzin Farzaneh, London, UK). Stable clones were selected in 0.5 mg/ml puromycin (Sigma), and grown in RPMI-1640 medium (Sigma) supplemented with 10% fetal calf serum (HyClone) and 2 mM glutamine (Sigma) at 378C in a 5% CO 2 humidi®ed incubator. Five`Jurkat-EBNA clones' were selected (JEB1, JEB2, JEB3, JEB4, JEB5).
Bone marrow screen JEB2 cells were stably transfected with a human bone marrow cDNA library (Clontech #HL1168x) in the episomal vector pDR2. Forty-eight hours following electroporation the cells were plated in soft agar (Longthorne and Williams, 1997) , in the presence of 5 ng/ml of the monoclonal (IgM) anti-human CD95 antibody IPO-4 (obtained from Dr S Sidorenko, University of Washington, USA). Low concentrations of antibody were used in order to more accurately assess the eects of potential mediators of apoptosis: in 5 ng/ ml IPO-4, Jurkat cells are routinely dead by 72 h. Following 3 weeks, with weekly renewals of anti-CD95 antibody, the surviving colonies were counted. CD95-resistant colonies were lysed and tested for the presence of episomal DNA, by PCR, using the Epstein-Barr Virus oriP sequence-speci®c primers DR1=5'-CGCTGCTGTCGGCGTCCACTCTC-3' and DR2=5'-CGCCTGCTTCTTCATTCTCCTTCG-3'. Once the presence of episomal DNA was con®rmed using the DR primers, insert-spanning primers (provided by Clontech) were used to determine the number of dierent sized inserts. The episomes were then extracted, according to the Clontech protocol, and transfected into bacteria for growth and analysis prior to functional con®rmation by re-transfection into JEB clones 1, 3, 4, 5. For the bacterial transformation, E. coli (strain DH10B) were electroporated at 1.8 kV, 200 O and 25 mF in 0.1 cm Bio-Rad electroporation cuvettes.
RT ± PCR
Total RNA from human spleen tissue was purchased from Clontech (#64034-1), and total RNA from 5610 4 Jurkat cells was made using RNAzol B (Biogenesis), according to manufacturer's guidelines. One mg total RNA was reverse transcribed using a random hexamer primer and AMV reverse transcriptase (Kramel Biotech), according to manufacturer's recommendations. One tenth of the reverse transcribed RNA was used in the PCR reactions. The various LUCA-15 transcripts were detected using either LU15(2) 5'-GCACGAC-TATAGGCATGACAT-3' with LU15(3) 5'-AGTCAAACTT-GTCTGCTCCA-3', LU15(2) with LS5 5'-GGCATTCTCAA-GGAGATTAG-3' or, LU15G 5'-GGACACATGTTCCTCA-CAATG-3' with LU15(3). All variant RT ± PCR transcripts were sequenced using an ABI Prism Dye Terminator Sequencing kit containing Amplitaq DNA Polymerase FS (Perkin-Elmer), according to the manufacturer's instructions. Clone 26 DNA was used in the PCR reaction as a positive control for primers LU15(2) and LS5 and a negative control for all other primer pairs. All reverse transcribed RNA samples were tested for integrity and genomic DNA contamination by PCR using HPRT primers: Exon 7 of the HPRT gene control transcript was detected using a primer with the sequence 5'-CTTGCTGGTGAAAAGGACC-3', and Exon 8 of the HPRT gene was detected using a primer with the sequence 5'-TCCCTGAAGTATTCATTATAGTG-3'. These primers amplify a product of 117 bp from RNA and 287 bp from DNA, as they span a 171 bp intron. Genomic DNA was used as a positive control for this PCR reaction.
Northern blot analysis
Three multiple tissue Northern blots were purchased from Clontech: (a) Human Immune System MTN Blot II (#7768-1); (b) Human Multiple Tissue MTN Blot (#7760-1); and (c) Cancer MTN Blot (#7757-1). Each lane contains 2 mg of poly(A) + RNA. Primers used to produce a Je2-speci®c hybridization probe were primers LS1: 5'-CTATGTTCTCT-TCACTGTC-3' and LS2: 5'-GGAACAAGTCTGTACAAT-3' (for relative positions in LUCA-15 see Figure 2 ). Primers used to produce a 5'-LUCA-15-speci®c hybridization probe were LU1: 5'-GTGAGTAGAACAGAGCGTAG-3', and LU3: 5'-TCTTCAAACTTAGGTCTGGG-3'. Primers used to obtain a 3'-LUCA-15-speci®c hybridization probe were LU4: 5'-CAGAAAGACGGGAGAAG-3' and LU5: 5'-ATC-TTTGTAGGAATCGG-3'.
Immunoblotting
Whole cell lysates were obtained in the following manner. 10 6 cells were harvested and washed twice with phosphate buered saline. Cell pellets were resuspended in lysis buer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.5% NP-40, 100 mM NaF, 1 mM EDTA, 1 mM EGTA, 8 mM PMSF, 10 mg/ml leupeptin, 20 mg/ml aprotinin), and centrifuged at 14 300 g for 10 min. Protein concentration in the supernatants was determined using the Bio-Rad protein assay kit. Fifty mg protein were added to sample buer (10% glycerol, 0.7 M b-ME, 3% SDS, 62 mM Tris-HCl, pH 6.8), boiled for 5 min, and loaded onto a 10% polyacrylamide gel along with a Rainbow marker (RPN756 Amersham). Following electrophoresis the protein was electroblotted onto Hybond-ECL membrane (Amersham). Membranes were blocked with 5% non-fat dry milk in TTBS (20 mM Tris-HCl, pH 7.5, 500 mM NaCl, 0.05% Tween-20), washed in TTBS, and probed using 3% non-fat dry milk. Primary antibodies were incubated overnight at 48C, and secondary antibodies were incubated for 1 h at 238C. Between probings, membranes were stripped in 100 mM b-ME, 2% SDS, 62.5 mM Tris-HCl, pH 6.7 for 30 min at 508C. Rabbits were immunized with peptide 323 (MGSDKRVSRTERSGR) incorporating the ®rst 15 amino acids of the LUCA-15 N-terminal putative protein coding sequence. Blots were probed with anti-LUCA-15 antibody, used at a 1 : 2500 dilution. Pre-immune serum was used at a 1 : 2500 dilution, and the peptide block was performed using 30 mg of peptide. Rabbit anti-human caspase-3 antibody (H-277, Santa Cruz Biotechnology) was used at a 1 : 500 dilution. Secondary antibody was a donkey anti-rabbit IgG, horseradish peroxidase linked whole antibody (N-934, Amersham), used at a 1 : 2500 dilution. Radiography was performed using an ECL chemiluminescence kit (Amersham).
Spleen screen
A Rapid-Screen Spleen cDNA Library Panel (Origene Technologies, Inc.) was used to identify cDNAs containing Je2 sequence according to the manufacturer's screening protocol. The Je2-speci®c primers used were LS1 and LS2 (see above).
Inducible gene expression
A zinc-inducible gene expression system was used (Sutherland et al., 2000) , incorporating the zinc-inducible pMTCB6 + expression vector (Cook et al., 1996) . Clone 26 was removed from the pCMV6-XL3 spleen cDNA library expression vector, by digestion with restriction endonucleases Sma1 and NotI, and directionally ligated into the previously EcoRV and NotI digested, dephosphorylated pMTCB6 + vector. pMTCB6 + /Clone 26 and pMTCB6 + were separately electroporated into Jurkat cells, and stable clones were selected by growth in 1.0 mg/ml geneticin (Sigma). Individual clones Jurkat/pMTCB6 + .1 and Jurkat/pMTCB6 + /Clone 26.4 were pre-incubated in 50 mM zinc sulfate (Sigma) for 50 h prior to exposure to 5 ng/ml CD95 antibody. Cells were grown for a further 38 h in the presence or absence of antibody. Viability was determined by vital dye staining, using 0.2% nigrosin (Sigma).
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